A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

This is a first-time-in-human (FTiH) Phase 1, multicenter, open-label, dose-escalation, and
dose-expansion study of MEDI0562 to evaluate the safety, tolerability, pharmacokinetics,
immunogenicity, pharmacodynamics and preliminary anti-tumor activity in adult subjects with
selected advanced solid tumors.

Inclusion Criteria:

- Subjects must have confirmed advanced solid tumor and have progressed, are refractory,
or are intolerant to standard therapy appropriate for tumor type. Subjects should not
have received more than 3 prior lines of therapy for recurrent or metastatic disease
including both standards of care and investigational therapies.

- Subjects must have at least 1 measurable lesion.

- Consent to provide archived tumor specimens

- Willingness to undergo pre-treatment and on-treatment biopsy.

- Adequate organ function.

- Use of highly effective contraception (females) or male condom plus spermicide
(males).

Exclusion Criteria:

- Prior treatment with TNFRSF agonists.

- Subjects who have received certain prior immunotherapy or had toxicities relating to
prior immunotherapy may not be permitted to enroll.

o Must not have required the use of additional immunosuppression other than
corticosteroids for the management of an adverse event.

- History of severe allergic reactions to any unknown allergens or any components of the
study drug formulations.

- Receipt of any conventional or investigational anticancer therapy within 28 days prior
to the first dose of MEDI0562.

- Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer
treatment.

- Unresolved toxicities from prior anticancer therapy.

- Any condition that, in the opinion of the investigator or sponsor, would interfere
with evaluation of the investigational product.